<DOC>
	<DOC>NCT01501435</DOC>
	<brief_summary>To investigate the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra</brief_summary>
	<brief_title>To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra</brief_title>
	<detailed_description>Study objectives - To compare the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra after a single oral administration in healthy male volunteers. - To evaluate the food-effect on pharmacokinetics of CJ-30039 after a single oral administration in healthy male volunteers.</detailed_description>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Male volunteers in the age between 20 and 55 years old BMI(Body Mass Index) in the range of 18.5 to 25kg/m2 Subject with no history of any significant chronic disease History of clinically significant allergies, including fenofibric acid or Fenofibrate History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, cardiovascular disease History of surgery except or gastrointestinal disease which might significantly change absorption of medicines Clinical laboratory test values are outside the accepted normal range AST(ASpartate Transaminase), ALT(ALanine Transaminase)( &gt; 1.25 times to normal range Total bilirubin &gt; 1.5 times to normal range BUN(Blood Urea Nitrogen) &gt; 25 mg/dL or Creatinine &gt; 1.4 mg/dL CK(Creatine Kinase) &gt; 1.25 times to normal range Estimated GFR(Glomerular Filtration Rate) &lt; 80 mL/min/1.73m2 Clinically significant vital sign SBP(Systolic Blood Pressure) ≤ 90 mmHg or SBP ≥ 150 mmHg DBP(Diastolic Blood Pressure) ≤ 50 mmHg or DBP ≥ 100 mmHg History of drug abuse or positive urine screen for drugs History of caffeine, alcohol, smoking abuse caffeine &gt; 5 cups/day alcohol &gt; 201g/week smoking &gt; 10 cigarettes/day Use of prescription only medicine and oriental medicine within the 14 days before dosing or use of nonprescription medicine within the 7 days before dosing Participated in a previous clinical trial within 60 days prior to dosing Donated blood within 60 days prior to dosing</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>